Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

VIDEO: What is the Mechanism of Action of Emgality® (galcanezumab-gnlm) in Migraine Prevention?

Emgality (galcanezumab) is a humanized IgG4 mAb that binds CGRP and prevents its biological activity without blocking the CGRP receptor.

Date of Last Review: September 14, 2021

Document Number: VV-MED-114530


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical